文献速递泌尿生殖与妇科肿瘤放疗

前列腺癌大分割质子治疗II期研究的长期结果:中度与极度大分割比较

Long-term results of a phase II study of hypofractionated proton therapy for prostate cancer: moderate versus extreme hypofractionation.
PubMed 文献 · Radiat Oncol · 2019-01-10

这项前瞻性II期研究将82例未接受雄激素剥夺治疗的T1-3bN0M0前列腺癌患者随机分入五种质子治疗大分割方案,本次探索性分析将方案归为中大分割组(52例)和极度大分割组(30例),中位随访7.5年,7年生化无失败生存率中度组76.2% vs 极度组46.2%(p=0.005),作者认为极度大分割疗效可能劣于中度大分割,需进一步研究确认。

要点

  • 7年生化无失败生存率中度大分割组76.2% vs 极度大分割组46.2%(p=0.005)。
  • 中危组7年生化无失败生存率中度大分割83.5% vs 极度大分割42.9%(p=0.018)。
  • 急性泌尿生殖系统毒性中度大分割组85% vs 极度大分割组57%(p=0.009)。

核心结论

  • 作者认为极度大分割的疗效可能劣于中度大分割,需进一步研究确认这些发现。

研究设计与样本

  • 前瞻性II期研究,82例未接受雄激素剥夺治疗的T1-3bN0M0前列腺癌患者随机分入五种质子治疗大分割方案。
  • 本次探索性分析将Arm 1-3归为中大分割组(52例),Arm 4-5归为极度大分割组(30例)。

主要发现

  • 中位随访7.5年(范围1.3-9.6年),7年生化无失败生存率中度大分割组76.2% vs 极度大分割组46.2%(p=0.005)。
  • 低危组7年生化无失败生存率中度大分割90.5% vs 极度大分割57.1%(p=0.154);中危组83.5% vs 42.9%(p=0.018);高危组41.7% vs 40.0%(p=0.786)。
  • 生化失败倾向于晚期事件,中位发生时间5年。
  • 急性泌尿生殖系统毒性中度大分割组85% vs 极度大分割组57%(p=0.009),晚期胃肠道和泌尿生殖系统毒性两组无差异。

关键数值与推荐

  • Arm 1:60 CGE/20次/5周;Arm 2:54 CGE/15次/5周;Arm 3:47 CGE/10次/5周;Arm 4:35 CGE/5次/2.5周;Arm 5:35 CGE/5次/4周。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 本文为探索性分析。
  • 作者结论指出需进一步研究确认这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We performed a prospective phase II study to compare acute toxicity among five different hypofractionated schedules using proton therapy. This study was an exploratory analysis to investigate the secondary end-point of biochemical failure-free survival (BCFFS) of patients with long-term follow-up. METHODS: Eighty-two patients with T1-3bN0M0 prostate cancer who had not received androgen-deprivation therapy were randomized to one of five arms: Arm 1, 60 cobalt gray equivalent (CGE)/20 fractions/5 weeks; Arm 2, 54 CGE/15 fractions/5 weeks; Arm 3, 47 CGE/10 fractions/5 weeks; Arm 4, 35 CGE/5 fractions/2.5 weeks; and Arm 5, 35 CGE/5 fractions/4 weeks. In the current exploratory analysis, these ardms were categorized into the moderate hypofractionated (MHF) group (52 patients in Arms 1-3) and the extreme hypofractionated (EHF) group (30 patients in Arms 4-5). RESULTS: At a median follow-up of 7.5 years (range, 1.3-9.6 years), 7-year BCFFS was 76.2% for the MHF group and 46.2% for the EHF group (p = 0.005). The 7-year BCFFS of the MHF and EHF groups were 90.5 and 57.1% in the low-risk group (p = 0.154); 83.5 and 42.9% in the intermediate risk group (p = 0.018); and 41.7 and 40.0% in the high risk group (p = 0.786), respectively. Biochemical failure tended to be a late event with a median time to occurrence of 5 years. Acute GU toxicities were more common in the MHF than the EHF group (85 vs. 57%, p = 0.009), but late GI and GU toxicities did not differ between groups. CONCLUSIONS: Our results suggest that the efficacy of EHF is potentially inferior to that of MHF and that further studies are warranted, therefore, to confirm these findings. TRIAL REGISTRATION: This study is registered at ClinicalTrials.gov, no. NCT01709253 ; registered October 18, 2012; retrospectively registered).

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Ha B, Cho KH, Lee KH, et al. Long-term results of a phase II study of hypofractionated proton therapy for prostate cancer: moderate versus extreme hypofractionation. Radiat Oncol. 2019. PMID: 30630500. doi:10.1186/s13014-019-1210-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。